While some insulin molecules may be locally synthesized and released by neurons in the CNS (such as the hippocampus, prefrontal cortex, but not glial cells) ( Metabolic impairment The brain is an organ that requires a lot of glucose to produce energy, with almost 70 percent of the energy used by neurons
A smaller measured volume does not automatically mean a safer dose
However, all these treatments are symptomatic and cannot prevent or reverse AD pathology ( Figure 1 ) ( Figure 1 Biological characteristics of GLP-1 In the 1980s, a new glucagon-like peptide, produced from proglucagon cleavage, was discovered to stimulate insulin secretion ( GLP-1, a 36-amino acid peptide, is produced in enteroendocrine L-cells of the distal small bowel and colon ( The effect of GLP-1 depends on blood glucose levels since it can only potentiate glucose-stimulated insulin secretion from islet beta cells in the hyperglycemic state rather than in the normal blood glucose state ( Tissue distribution of GLP-1R GLP-1 mediates its effects by binding to its receptor, the GLP-1R, which is a sevenfold transmembrane G-coupled receptor that increases levels of cAMP by activating adenylate cyclase ( In the peripheral system, GLP-1R mediates the actions of GLP-1 via the incretin axis, in which stimulation of the GLP-1R with GLP-1 primarily triggers insulin release from islet cells in a glucose-dependent manner and inhibits glucagon secretion from islet cells ( s coupling pathway ( s , upregulating of cAMP, and subsequently activating of PKA ( + efflux, repolarizing the cell and allowing increased calcium influx through voltage-dependent calcium channels, resulting in the exocytosis of insulin from -cells ( In the CNS, GLP-1 also exert neuroprotective and neurotropic effects by binding to GLP-1R ( GLP-1R agonists Several GLP-1R agonists, which mainly delay protease DPP-4 metabolism to overcome the problem with the rapid inactivation of GLP-1, have been developed ( Figure 2 ) ( Figure 2 Exenatide, a peptide of 39 amino acids, has a much slower metabolism than endogenous GLP-1 (half-life of 3-4 h) (120)
These reports are intriguing and deserve further scientific exploration to understand potential mechanisms, such as the modification of gut microbiota or inflammation pathways
Pharmaceutical companies are researching the formulation of different transdermal patches for weight loss and diabetes, using efficient delivery technologies
Images such as these encapsulate treatment outcomes in a simple format that is easy to understand, even for people not familiar with the nuances of scientific publications
